Harvey Berger

Last updated
Harvey Berger
Harvey Berger M.D.jpg
Born (1950-06-06) June 6, 1950 (age 73)
Alma mater Colgate University (1972, B.A.)
Yale School of Medicine (1977, M.D.)
Occupation(s)Founder and Former Chairman & CEO of ARIAD Pharmaceuticals
Board member of Dana–Farber Cancer Institute
SpouseChrysanthi Berger (m. 2002)
Children2

Harvey J. Berger is an American physician-scientist, entrepreneur and biotechnology executive. He was the founder and chairman and chief executive officer of ARIAD Pharmaceuticals, Inc. for 25 years, starting in 1991 and became advisor to the board in 2016. He was also executive chairman at Medinol, Inc from 2017 to 2018. In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees.

Contents

Early life and education

Berger received his B.A. in Biology from Colgate University in 1972 and received his M.D. from Yale School of Medicine in 1977. [1] [2] He completed further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital. [2]

Career

From 1986 until 1991, Berger held executive management positions at Centocor, Inc. including executive vice president and president of the Research and Development Division. [3] He led the development of Remicade® (infliximab), formerly known as Centara, a drug for the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis and rheumatoid arthritis, ReoPro® (abciximab), formerly known as CentoRx, a drug for the prevention of ischemic complications in patients with CAD undergoing percutaneous interventions, [4] [5] and the cancer diagnostic test, CA125, to evaluate patients with ovarian cancer. [6] [7]

In 1991, Berger founded ARIAD Pharmaceuticals in Cambridge, Massachusetts. [8] [9] He served as chairman and CEO from 1991 to 2015. [9] [2] In 1992, ARIAD raised $46 million, the largest single round of financing for a startup in the biotechnology industry at the time. [10] ARIAD's plan was to develop drugs that would interfere with communication signals within cells, rather than on the cell surface or in between cells. [10] In 1994, ARIAD filed for an initial public offering and was listed on the NASDAQ market. [11] [12]

In 2000, Berger focused ARIAD on oncology, based on recent discoveries in the human genome. [13] Under Berger's leadership, ARIAD grew to over 365 U.S. employees and established a European headquarters in Lausanne, Switzerland. [14] [15]

While Berger was CEO, ARIAD developed five new medicines including the blood-cancer drug Iclusig, Brigatinib, a lung cancer treatment and AP32788 (now known as TAK788), a new medicine for lung cancer with novel mutated genetic targets. [9] [16]

Brigatinib is approved for use in the U.S. [17] and Europe, [18] [19] and TAK788 is continuing a global phase 3 trial. [20]

At the end of 2015, Berger retired from ARIAD and became an advisor to the board of directors. [9] [21] In early 2017, ARIAD was acquired by Takeda Pharmaceuticals, Ltd. for $5.2 billion, becoming part of Takeda Oncology. [22]

In February 2017, Medinol, Inc. announced that Berger would be serving as its executive chairman. [23] On the global management team, his focuses at Medinol would include business management, global strategy, new business and technology initiatives, as well as improving operational efficiency as the company expands worldwide. [24] [3] Berger's role at Medinol was said to include working with their core business of interventional cardiovascular devices, along with its new businesses developing percutaneous aortic valves, sub-millimeter implantable sensors, and related products. [24] He retired from Medinol at the end of 2018. [25] In 2019, Berger retired as chairman and chief executive officer emeritus of ARIAD. [25]

Berger has served on the Board of Trustees at Concord Academy. [26]

Berger has held senior academic and administrative roles at Emory University, Yale University and the University of Pennsylvania. [3] [24] He was also a member of the Dean's Council of Yale University School of Medicine. [2] During his time at Emory, Berger led a program for developing cardiovascular single-photon emission computed tomographic (SPECT) imaging, supported by General Electric Medical Systems. [27] He and other colleagues at Emory collaborated on the development of new quantitative techniques for cardiac SPECT imaging. [28]

Berger has contributed to a wide range of medical journals including the New England Journal of Medicine and American Journal of Cardiology, [29] [30] and has been interviewed by Fox Business [31] [32] [33] [34] and CNBC. [35] He was also an established investigator of the American Heart Association. [3]

Awards

In 2013, Berger was awarded the Ernst & Young Entrepreneur of the Year Award for the New England Region. The award recognizes success in innovation, financial performance, personal commitment to their business communities and other areas. [36] Also in 2013, Berger was awarded a Gold Stevie Award. [37] [38]

Personal life and philanthropy

Berger resides in Palm Beach, Florida, with his wife Chrysanthi and their two daughters, Isabella Grace Berger and Nicole Elizabeth Berger, an actress. [39] [40] Harvey and Chrysanthi Berger have supported the Palm Beach Day Academy, the American Cancer Society, and the Dana–Farber Cancer Institute. [41] [42] [43] In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees, the governing board of the organization. [44]

Related Research Articles

<span class="mw-page-title-main">Pharmaceutical Research and Manufacturers of America</span> Trade group

Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.

<span class="mw-page-title-main">Methotrexate</span> Chemotherapy and immunosuppressant medication

Methotrexate (MTX), formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn's disease. It can be given by mouth or by injection.

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Pharmaceutical company in Asia

The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana–Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

<span class="mw-page-title-main">ARIAD Pharmaceuticals</span> Defunct oncology company

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.

<span class="mw-page-title-main">ALK inhibitor</span>

ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 2020, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient.

<span class="mw-page-title-main">Brigatinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

Laurie Hollis Glimcher is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a Member of the American Philosophical Society in 2019.

<span class="mw-page-title-main">Alex Gorsky</span> American businessman (born 1960)

Alex Gorsky is an American businessman. He is the former Chairman and Chief Executive Officer of Johnson & Johnson. Gorsky stepped down as CEO of Johnson & Johnson in January 2022 and was succeeded by Joaquin Duato. He was the seventh person who served as the company's chairman and chief executive officer since it became a publicly traded company in 1944.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Edward J. Benz Jr. is the former president of Dana–Farber Cancer Institute in Boston, Massachusetts., and the Richard and Susan Smith Professor of Medicine as well as a professor of genetics at Harvard Medical School.

The Institute for Clinical and Economic Review (ICER) is a Boston-based independent nonprofit organization that seeks to place a value on medical care by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures.

<span class="mw-page-title-main">Jeffrey Leiden</span> CEO of biotechnology company

Jeffrey Leiden, M.D., Ph.D. is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.

<span class="mw-page-title-main">Philip Kantoff</span> Medical researcher

Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.

The MIT Abdul Latif Jameel Clinic for Machine Learning in Health is a research center at the Massachusetts Institute of Technology (MIT) in the field of artificial intelligence (AI) and health sciences, including disease detection, drug discovery, and the development of medical devices. The MIT Jameel Clinic also supports the commercialization of solutions through grant funding, and has partnered with pharmaceutical companies, like Takeda and Sanofi, to forge collaborations between research and development functions and MIT researchers.

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

Matthew Langer Meyerson is an American pathologist and the Charles A. Dana Chair in Human Cancer Genetics at the Dana-Farber Cancer Institute. He is also director of the Center for Cancer Genomics at the Dana-Farber Cancer Institute, and the Director of Cancer Genomics at the Broad Institute of MIT and Harvard.

The Wyss Institute for Biologically Inspired Engineering is a cross-disciplinary research institute at Harvard University focused on bridging the gap between academia and industry by drawing inspiration from nature's design principles to solve challenges in health care and the environment. It is focused on the field of biologically inspired engineering to be distinct from bioengineering and biomedical engineering. The institute also has a focus on applications, intellectual property generation, and commercialization. The Wyss Institute is located in Boston's Longwood Medical Area and has 375 full-time staff. The Wyss is organized around eight focus areas, each of which integrate faculty, postdocs, fellows, and staff scientists. The focus areas are bioinspired therapeutics & diagnostics, diagnostics accelerator, immuno-materials, living cellular devices, molecular robotics, 3D organ engineering, predictive bioanalytics and synthetic biology.

References

  1. ↑ "A showcase of alumni talent (The Colgate Scene, September 2002)". www4.colgate.edu. Retrieved 2017-09-25.
  2. 1 2 3 4 "MIT Sloan BioInnovations 2011". web.mit.edu. Retrieved 2017-09-20.
  3. 1 2 3 4 Bader, Emily (2017-02-16). "Medinol appoints executive chairman of Medinol US | NJBIZ". NJBIZ. Retrieved 2017-09-23.
  4. ↑ Letter, The Pharma. "US Approval For Centocor's ReoPro – Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2017-09-25.
  5. ↑ "Biotechnology Report, Medicines in Development, 2006 | Interleukin 2 | Monoclonal Antibody". Scribd. Retrieved 2017-09-25.
  6. ↑ "Centocor CA 125 II, New Version of CA 125 Assay, Is Now Available | Cancer Network". www.cancernetwork.com. Oncology NEWS International Vol 4 No 5. 4 (5). May 1995. Retrieved 2018-03-20.
  7. ↑ Matsukura, A.; Nakazawa, Y.; Hama, S. (November 1989). "[A shortened method for the assay with Centocor radioimmunoassay kit]". Radioisotopes. 38 (11): 469–472. doi: 10.3769/radioisotopes.38.11_469 . ISSN   0033-8303. PMID   2595020.
  8. ↑ "Ariad moving to new Kendall Square headquarters – The Boston Globe". BostonGlobe.com. Retrieved 2017-09-24.
  9. 1 2 3 4 "Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'". www.bizjournals.com. Retrieved 2017-09-24.
  10. 1 2 Pollack, Rew (1992-03-27). "COMPANY NEWS; Ariad Raises $46 Million In Placement". The New York Times. ISSN   0362-4331 . Retrieved 2017-09-25.
  11. ↑ "Equity Issues This Week". The New York Times. 1994-05-16. ISSN   0362-4331 . Retrieved 2017-09-25.
  12. ↑ "Ariad Pharmaceuticals, Inc. (ARIA) Stock Higher on Takeda Buyout News". NASDAQ.com. 2017-01-09. Retrieved 2017-09-25.
  13. ↑ "Interview: Harvey Berger and Timothy Clackson, Ariad". www.pmlive.com. 2013-10-14. Retrieved 2017-09-20.
  14. ↑ "Ariad's Harvey Berger says he's 'absolutely' secure in his role as CEO". www.bizjournals.com. Retrieved 2017-09-25.
  15. ↑ "Ariad sells European operations for $140M upfront plus royalties". www.bizjournals.com. Retrieved 2017-09-25.
  16. ↑ "Positive Preclinical Results for Lung Cancer Drug Announced at Annual Meeting of Cancer Research – Lung Disease News". Lung Disease News. 2016-04-22. Retrieved 2017-09-24.
  17. ↑ Research, Center for Drug Evaluation and (2020-05-26). "FDA approves brigatinib for ALK-positive metastatic NSCLC". FDA.
  18. ↑ "BRIEF-Takeda Says European Commission Approved Alunbrig As A First-Line Treatment For ALK+ NSCLC". Reuters. 2020-04-06. Retrieved 2020-06-26.
  19. ↑ McKee, Selina (2020-04-08). "Expanded EU approval for Takeda's Alunbrig". PharmaTimes. Retrieved 2020-06-26.
  20. ↑ "Takeda's Approval and Other News: The Good, Bad And Ugly of Biopharma". 25 May 2020.{{cite web}}: CS1 maint: url-status (link)
  21. ↑ "ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer". ARIAD Pharmaceuticals, Inc. Retrieved 2017-09-24.
  22. ↑ "Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'". www.bizjournals.com. Retrieved 2017-09-23.
  23. ↑ "Berger named to post at Medinol – The Boston Globe". BostonGlobe.com. Retrieved 2017-09-25.
  24. 1 2 3 "Medinol hires Harvey Berger as executive chairman of its US operations". Cardiovascular Business. Retrieved 2017-09-23.
  25. 1 2 "Harvey Berger | About". Harvey Berger. Retrieved 2020-06-26.
  26. ↑ "CA Magazine Fall 2018". Issuu. Retrieved 2020-06-26.
  27. ↑ DePasquale, E. E.; Nody, A. C.; DePuey, E. G.; Garcia, E. V.; Pilcher, G.; Bredlau, C.; Roubin, G.; Gober, A.; Gruentzig, A. (1988-02-01). "Quantitative rotational thallium-201 tomography for identifying and localizing coronary artery disease". Circulation. 77 (2): 316–327. doi: 10.1161/01.CIR.77.2.316 . ISSN   0009-7322. PMID   3257422.
  28. ↑ Berger, Harvey J.; Eisner, Robert; DePuey, E. Gordon; Patterson, Randolph (1984-11-01). "New Vistas in Cardiovascular Nuclear Medicine". Journal of Nuclear Medicine. 25 (11): 1254–1258. ISSN   0161-5505. PMID   6333498.
  29. ↑ Ziegler, Elizabeth J.; Fisher, Charles J.; Sprung, Charles L.; Straube, Richard C.; Sadoff, Jerald C.; Foulke, Garrett E.; Wortel, Cornelis H.; Fink, Mitchell P.; Dellinger, R. Phillip (1991). "Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin". New England Journal of Medicine. 324 (7): 429–436. doi:10.1056/nejm199102143240701. PMID   1988827.
  30. ↑ Johnstone, David E.; Sands, Milton J.; Berger, Harvey J.; Reduto, Lawrence A.; Lachman, Anthony S.; Wackers, Frans J. Th; Cohen, Lawrence S.; Gottschalk, Alexander; Zaret, Barry L. (1980-06-01). "Comparison of exercise radionuclide angiocardiography and thallium-201 myocardial perfusion imaging in coronary artery disease". American Journal of Cardiology. 45 (6): 1113–1119. doi:10.1016/0002-9149(80)90467-1. ISSN   0002-9149. PMID   7377108.
  31. ↑ "Ariad CEO on Developing New Drugs". Fox Business. 2011-07-15. Retrieved 2017-11-10.
  32. ↑ "Ariad CEO on the Three Drugs in the Pipeline for Cancer Treatment". Fox Business. 2011-11-10. Retrieved 2017-11-10.
  33. ↑ "Ariad Pharmaceuticals Working on Cancer 'Miracle Pill'". Fox Business. 2012-08-03. Retrieved 2017-11-10.
  34. ↑ "Ariad Pharmaceuticals CEO on a New Leukemia Drug". Fox Business. 2012-06-08. Retrieved 2017-11-10.
  35. ↑ Chang, Kirsten (2012-06-04). "Cramer Interviews Ariad Pharma CEO". CNBC. Retrieved 2017-11-10.
  36. ↑ AOL Staff. "ARIAD Chief Executive Officer, Harvey J. Berger, M.D., Recognized as 2013 Ernst & Young Entrepreneur". AOL.com. Retrieved 2017-09-21.
  37. ↑ "ARIAD Honored With Gold Stevie Awards As Pharmaceutical Company Of The Year At 2013 American Business Awards". The Street. 18 June 2013. Archived from the original on 26 September 2017.
  38. ↑ "Harvey J. Berger, M.D. '77 Appointed Executive Chairman, Medinol Inc". Yale School of Medicine. Retrieved 2020-06-26.
  39. ↑ "Palm Beach 13-year-old gets Broadway bash – and a visit from Flo Rida". palmbeachdailynews. Retrieved 2017-09-23.
  40. ↑ "Alumni > Autumn 2008 | Yale Medicine". ymm.yale.edu. Retrieved 2017-11-10.
  41. ↑ "'Jukebox Hero' Gramm brings '80s to life for American Cancer Society". palmbeachdailynews. Retrieved 2017-11-10.
  42. ↑ "MAD, PMP, HSS, and PBDA". New York Social Diary. 2017-03-20. Retrieved 2017-11-10.
  43. ↑ Donnelly, Shannon. "Palm Beach society: Katie Couric shares slices of life at Dana–Farber Cancer Institute donors dinner". Sarasota Herald-Tribune. Retrieved 2020-06-26.
  44. ↑ "Dana–Farber Cancer Institute appoints six new members to Board of Trustees – Dana–Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 2018-03-20.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.